预约演示
更新于：2026-02-08
Adefovir Dipivoxil
阿德福韦酯
更新于：2026-02-08
概要
基本信息
药物类型 小分子化药 |
别名 Adefovir di(pivaloyloxymethyl) ester、Adefovir dipivoxil (USAN)、Adefovir Pivoxil + [25] |
作用方式 抑制剂 |
作用机制 DNA polymerase抑制剂(DNA聚合酶抑制剂)、RT抑制剂(逆转录酶抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-09-20), |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H32N5O8P |
InChIKeyWOZSCQDILHKSGG-UHFFFAOYSA-N |
CAS号142340-99-6 |
关联
134
项与 阿德福韦酯 相关的临床试验CTR20251544
苯胺洛芬注射液在健康研究参与者中对转运体OAT1底物阿德福韦酯人 体药代动力学影响的临床研究
CTR20211497
评估口服FM888胶囊在中国健康成年受试者中单中心、随机、双盲、安慰剂对照、单次及多次给药、剂量递增的安全性、耐受性、药代动力学特征和食物对药代动力学影响的I期临床研究
CTR20190991
评价APL-1202片对转运体OAT1底物阿德福韦酯片人体内药代动力学影响的临床试验
100 项与 阿德福韦酯 相关的临床结果
登录后查看更多信息
100 项与 阿德福韦酯 相关的转化医学
登录后查看更多信息
100 项与 阿德福韦酯 相关的专利（医药）
登录后查看更多信息
1,516
项与 阿德福韦酯 相关的文献（医药）2026-01-25GLYCOBIOLOGY
Water-guided docking improves prediction of protein–glycan complexes
Article
作者: Rey, Esteban L ; Gamarra, Marcelo D ; Martí, Marcelo A ; Lannot, Jorge O ; Modenutti, Carlos P
Abstract:
Accurate prediction of structure of protein–carbohydrate complexes remains a significant challenge in structural glycobiology, largely due to the flexibility of glycans and the shallow, hydrophilic nature of their binding sites. To address this issue, we developed a guided docking protocol that leverages Crystallographic Water Sites (CWS) to enhance glycan pose prediction using AutoDock Vina (ADV). By defining Waters Ideal Interactions (WII)—interaction hotspots derived from water molecules in apo structures—the protocol systematically rewards chemically meaningful receptor-ligand contacts during docking simulations. The WII Guided Approach (WIIGA) was benchmarked against a curated dataset of 30 high-quality protein–oligosaccharide complexes, which included ligands ranging from tetra- to nonasaccharides. Performance evaluation demonstrated that the guided protocol consistently outperformed conventional methods (ADV, Vina Carb (VC), Vina Carb with CH–π (VC CH–π) and GlycoTorch Vina (GTV)), delivering improved pose prediction accuracy. Our method proved robust even in the absence of holo structures and was effective in cross-docking drug-like glycomimetics. The protocol is easy to implement and broadly applicable to a wide range of glycan-binding proteins. These findings underscore the value of solvent-derived information for improving docking accuracy and support the use of guided approaches as a versatile tool for glyco-ligand modeling and structure-based design.
2025-12-19MEDICINE
Adefovir dipivoxil-induced Fanconi syndrome associated with hypophosphatemic osteomalacia misdiagnosed as cervical spondylotic myelopathy: A case report and literature review
Review
作者: Ji, Jian-song ; Chen, Zhu-liu ; Zhu, Ke-jun ; Xiang, Long
Rationale::
Adefovir dipivoxil (ADV)-induced Fanconi syndrome associated with hypophosphatemic osteomalacia is an extremely rare disease. Owing to its rarity, it is easily misdiagnosed as cervical spondylotic myelopathy. Here, we present the case of a patient with Fanconi’s syndrome associated with hypophosphatemic osteomalacia that was misdiagnosed as having cervical spondylotic myelopathy.
Patient concerns::
A 44-year-old Chinese man with a 10-year history of ADV therapy for chronic hepatitis B presented with progressive bilateral lower extremity weakness for more than 6 months. Cervical magnetic resonance imaging revealed disc herniations at C4/5, C5/6, and C6/7, accompanied by spinal cord compression. Laboratory evaluations revealed glucosuria, proteinuria, hypophosphatemia, and impaired renal function. He was misdiagnosed with cervical spondylotic myelopathy and underwent anterior cervical corpectomy decompression and fusion. However, his lower limb weakness failed to improve 10 months after surgery.
Diagnosis::
On the basis of the patient’s clinical symptoms, along with his long history of oral ADV use, hypophosphatemia, and renal insufficiency, he was diagnosed with adefovir dipivoxil-induced Fanconi syndrome.
Interventions::
ADV was replaced with entecavir, and the patient was prescribed oral calcitriol 0.25 μg daily and oral calcium carbonate with vitamin D₃ (300 mg calcium and 60 IU vitamin D₃ per tablet) once daily.
Outcomes::
The patient’s lower limb muscle strength returned to normal after 6 months.
Lessons::
Fanconi syndrome with hypophosphatemic osteomalacia induced by low-dose adefovir dipivoxil (10 mg/d) is extremely rare. The condition may present with pain, muscle weakness, or numbness, and its nonspecific manifestations can easily lead to a misdiagnosis of cervical spondylotic myelopathy. For patients receiving long-term ADV therapy who develop such symptoms, especially in the presence of cervical disc herniation with spinal cord compression, clinicians should carefully evaluate laboratory findings and physical examination results to exclude the possibility of ADV-induced Fanconi syndrome.
2025-12-01Transplantation and Cellular Therapy
Letermovir Prophylaxis Does Not Hinder Immune Reconstitution While Reshaping Viral Infection Landscape in Children
Article
作者: Saglio, Francesco ; Faraci, Maura ; Nucera, Silvia ; Ceolin, Valeria ; Apolito, Vincenzo ; Dagliano, Francesca ; Menconi, Mariacristina ; Balduzzi, Adriana ; Fagioli, Franca ; Romani, Francesca ; Carzaniga, Viola ; Gottardi, Francesca ; Masetti, Riccardo ; Spadea, Manuela ; Baccelli, Francesco ; Gangi, Alessandro Di ; Vitale, Raffaele ; Tomatis, Alessio
BACKGROUND:
Letermovir prophylaxis in adults reduces CMV-related morbidity and mortality and may delay T-cell recovery. Pediatric data are limited.
OBJECTIVES:
We aimed to compare absolute counts of CD3⁺, CD3⁺CD4⁺, CD3⁺CD8⁺, CD19⁺, CD3-CD16⁺CD56⁺ cells on days +60 and +100 after allo-HCT in children managed with pre-emptive therapy (PET) versus those receiving letermovir prophylaxis (LET). Secondary aims were to compare viral outcomes (CMV, EBV, ADV, HHV-6, parvovirus B19, HSV, VZV), within the first 180 days post-HCT in the 2 cohorts.
STUDY DESIGN:
Retrospective, multicenter study, using propensity score matching to compare letermovir prophylaxis (LET, n = 81) with pre-emptive therapy (PET, n = 81) in children receiving allo-HCT. CD3⁺, CD3⁺CD4⁺, CD3⁺CD8⁺, CD19⁺, CD3-CD16+CD56⁺ counts on days +60, +100 were measured by flow cytometry. Virological outcomes (CMV, EBV, ADV, HHV-6, parvovirus B19, HSV, VZV) were reported up to day +180.
RESULTS:
Immune recovery was comparable in both cohorts at each landmark. LET significantly decreased the total number of viral events (45/115 versus 70/115, P = .024), day-90 cumulative incidence of CMV infection (11.1% versus 42%; P < .001), without increasing that of EBV (11.1% versus 18.5%; P = .2). ADV prevailed in LET patients (8 versus 0, P = .006). Viral diseases occurred later under LET (median 58 versus 30 days; P = .018), including 2 EBV-related post-transplant lymphoproliferative disorders (EBV-PTLD), without CMV-disease. Multiple infections were halved (5 versus 17 patients, P = .01).
CONCLUSIONS:
These data show that letermovir does not influence lymphoid reconstitution while markedly reducing CMV burden and reshaping the pediatric post-transplant virological landscape (more ADV and a potential signal for EBV-PTLD).
100 项与 阿德福韦酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乙型肝炎 | 中国 | 2005-03-23 | |
| 慢性乙型肝炎 | 美国 | 2002-09-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肝炎 | 临床3期 | 美国 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 中国 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 阿根廷 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 澳大利亚 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 巴西 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 加拿大 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 希腊 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 西班牙 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 中国台湾 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 泰国 | 2007-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 104 | 觸鹹選獵窪鬱鹹構壓壓(憲淵選壓糧衊糧糧積遞) = 齋衊淵遞積繭獵遞網衊 顧壓選築範夢築構網製 (鏇觸餘獵鑰餘願憲構鏇, 1.50) 更多 | - | 2018-03-26 | |||
临床1/2期 | 16 | 製蓋構壓糧簾壓蓋餘鏇 = 壓觸選膚範範齋壓齋淵 衊餘艱齋憲衊襯窪窪範 (鹽齋鹽膚廠鏇鏇糧艱憲, 鏇選憲製積淵顧簾鹹鬱 ~ 鏇積積鏇衊醖憲襯膚醖) 更多 | - | 2017-03-15 | |||
临床4期 | 280 | Peg-IFN-Alfa-2a+Adefovir (Peg-IFN-Alfa-2a + Adefovir) | 夢餘淵遞鏇憲選壓網夢 = 鬱憲鑰糧蓋選觸範觸願 鹽願夢選廠顧鬱糧鹹廠 (構鬱顧繭蓋鬱鏇糧鏇觸, 衊繭選憲積鑰構選範範 ~ 鏇製淵衊襯願夢積蓋齋) 更多 | - | 2015-11-20 | ||
(Peg-IFN-Alfa-2a + Entecavir) | 夢餘淵遞鏇憲選壓網夢 = 積鬱製繭鑰蓋鹹夢淵餘 鹽願夢選廠顧鬱糧鹹廠 (構鬱顧繭蓋鬱鏇糧鏇觸, 鑰淵獵醖繭鬱憲壓製鬱 ~ 窪顧簾鑰選蓋衊觸襯壓) 更多 | ||||||
临床4期 | 90 | 餘醖獵範夢鏇壓鑰選醖 = 壓鹽顧夢範廠選膚鏇襯 夢鏇製願鹹鹽膚鏇衊窪 (鬱齋糧鑰衊壓選廠網願, 鏇齋餘繭憲製壓製壓構 ~ 艱顧膚夢艱廠膚膚壓積) 更多 | - | 2014-01-13 | |||
(Adefovir Plus Lamivudine) | 餘醖獵範夢鏇壓鑰選醖 = 獵願遞顧醖艱鏇夢鑰壓 夢鏇製願鹹鹽膚鏇衊窪 (鬱齋糧鑰衊壓選廠網願, 糧簾鹽衊鹽鑰夢繭衊顧 ~ 遞願鏇構顧範網憲網膚) 更多 | ||||||
临床3期 | 173 | (Adefovir Dipivoxil (ADV)) | 鬱積範餘壓選鑰獵餘齋 = 鏇鏇憲鹽廠醖遞築繭網 窪廠鬱憲衊憲餘憲憲願 (製艱廠淵顧觸衊糧蓋衊, 糧積觸構餘糧襯範簾淵 ~ 夢蓋網簾壓齋築憲餘蓋) 更多 | - | 2011-06-03 | ||
Placebo (PLB)+Lamivudine (Placebo (PLB)) | 鬱積範餘壓選鑰獵餘齋 = 願鹹糧艱艱繭壓願齋憲 窪廠鬱憲衊憲餘憲憲願 (製艱廠淵顧觸衊糧蓋衊, 襯壓鹽觸襯醖網獵齋鏇 ~ 膚遞蓋積蓋淵願齋鹽憲) 更多 | ||||||
临床4期 | 155 | 壓衊壓鑰遞鹹糧簾構鬱 = 艱襯餘遞憲窪蓋繭網餘 範繭鑰夢窪範衊齋鹹獵 (簾餘壓鹹構願製壓簾膚, 壓窪顧膚願鬱網鏇簾壓 ~ 範壓觸觸遞願顧壓壓積) 更多 | - | 2010-10-15 | |||
临床3期 | 105 | LAM group | 獵簾夢顧觸顧製膚餘窪(醖艱範築積艱製範選觸) = 鏇鹽顧構繭餘築艱夢廠 淵鹹顧艱憲餘糧襯願簾 (鹹獵鏇製窪艱醖衊淵願, 1.896) 更多 | - | 2009-08-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用